Cargando…

P1227: COMPREHENSIVE MOLECULAR SUBTYPING OF DIFFUSE LARGE B-CELL LYMPHOMA CELL LINES AND ASSOCIATION WITH TAFASITAMAB ACTIVITY

Detalles Bibliográficos
Autores principales:	Arora, Arshi, Patra-Kneuer, Maria, Chang, Gaomei, Kuffer, Christian, Grau, Michael, Zapukhlyak, Myroslav, Blair, Derek, Ilieva, Kristina, Heitmueller, Christina, Lenz, Georg, Schaffer, Michael, Alvarez Arias, Diana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430906/ http://dx.doi.org/10.1097/01.HS9.0000971800.69573.fd

Ejemplares similares

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma
por: Patra-Kneuer, Maria, et al.
Publicado: (2023)

Preclinical study of CD19 detection methods post tafasitamab treatment
por: Ilieva, Kristina, et al.
Publicado: (2023)

Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy
por: Her, Jung Hyun, et al.
Publicado: (2022)

COLLABORATION AGREEMENT No. K1227
por: The European Organisation for Nuclear Research, CERN, et al.
Publicado: (2006)

COLLABORATION AGREEMENT K1227/AT
por: THE EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH, CERN, et al.
Publicado: (2006)

The use of tafasitamab in diffuse large B-cell lymphoma
por: Düll, Johannes, et al.
Publicado: (2021)

1227. Plazomicin Susceptibility Testing using ETEST(®) MIC for Enterobacterales
por: Ying, Yun, et al.
Publicado: (2020)

Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
por: Salles, Gilles, et al.
Publicado: (2021)

mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma
por: Xu, Wendan, et al.
Publicado: (2022)

1227. Development of a Clinical Prediction Model for Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Jorgensen, Sarah, et al.
Publicado: (2018)

1227. Candida Sternal Wound Infections After Cardiac Operations: Uncommon but Deadly
por: Seo, Jung M, et al.
Publicado: (2022)

Pityriasis lichenoides chronica in a patient on tafasitamab and lenalidomide therapy for diffuse large B-cell lymphoma
por: Roster, Katie, et al.
Publicado: (2023)

Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
por: Abdulhaq, Haifaa, et al.
Publicado: (2023)

miR-1227 Targets SEC23A to Regulate the Shedding of Large Extracellular Vesicles
por: Chin, Andrew, et al.
Publicado: (2021)

Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma
por: Sun, Kaiyan, et al.
Publicado: (2023)

Transformed Waldenström Macroglobulinemia Responsive to Tafasitamab Plus Lenalidomide: A Case Report
por: Nasir, Syed Alishan, et al.
Publicado: (2022)

1227. Analysis of Prescriber Interaction with an Electronic Antibiotic Time-out Best Practice Alert
por: Ackley, Tyler, et al.
Publicado: (2023)

Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Nedved, Adrienne, et al.
Publicado: (2023)

Molecular profiling of EBV associated diffuse large B-cell lymphoma
por: Frontzek, Fabian, et al.
Publicado: (2023)

Primary Anti-D Alloimmunization Induced by "Asian Type" RHD (c.1227G>A) DEL Red Cell Transfusion
por: Yang, Hyung-Seok, et al.
Publicado: (2015)

miR-1227-3p participates in the development of fetal growth restriction via regulating trophoblast cell proliferation and apoptosis
por: Cui, Jiawen, et al.
Publicado: (2022)

Long noncoding RNA OR3A4 promotes the proliferation and invasion of osteosarcoma cells by sponging miR-1227-5p
por: Yang, Changcheng, et al.
Publicado: (2020)

Circular RNA hsa_circ_0000658 inhibits osteosarcoma cell proliferation and migration via the miR‐1227/IRF2 axis
por: Jiang, Xin, et al.
Publicado: (2020)

Evaluation of intraoperative touch imprint cytology on axillary sentinel lymph nodes in invasive breast carcinomas, a retrospective study of 1227 patients comparing sensitivity in the different tumor subtypes
por: Pétursson, Hafsteinn Ingi, et al.
Publicado: (2018)

Suppressor of Ty 16 promotes lung cancer malignancy and is negatively regulated by miR‐1227‐5p
por: Yang, Lu, et al.
Publicado: (2020)

1227. Replacement and Rerouting of Pipes to Remediate Intractable Contamination of Potable Water Fixtures in a Pair of ICU Rooms
por: Carroll, David M, et al.
Publicado: (2019)

Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
por: Büchold, Christian, et al.
Publicado: (2022)

Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL
por: Tabbara, Nadeem, et al.
Publicado: (2021)

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
por: Delgado, Julio, et al.
Publicado: (2021)

Sequencing and comparative genomic analysis of 1227 Felis catus cDNA sequences enriched for developmental, clinical and nutritional phenotypes
por: Irizarry, Kristopher J, et al.
Publicado: (2012)

Overexpression of Circular RNA circ_0013587 Reverses Erlotinib Resistance in Pancreatic Cancer Cells Through Regulating the miR-1227/E-Cadherin Pathway
por: Xu, Huiting, et al.
Publicado: (2021)

1227 Familiality of fatal measles infections in Iceland, 1882. Analysis of a reconstructed patient cohort from a major epidemic
por: Gottfredsson, Magnus, et al.
Publicado: (2014)

PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA
por: Belada, D., et al.
Publicado: (2022)

P1227: POLATUZUMAB VEDOTIN, RITUXIMAB, AND BENDAMUSTINE COMBINATION IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-WORLD DATA FROM TURKEY
por: Dal, M. S., et al.
Publicado: (2022)

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2021)

P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS
por: Rosenthal, Allison, et al.
Publicado: (2023)

The Oral Transglutaminase 2 Inhibitor ZED1227 Accumulates in the Villous Enterocytes in Celiac Disease Patients during Gluten Challenge and Drug Treatment
por: Isola, Jorma, et al.
Publicado: (2023)

Pan-cancer identification of clinically relevant genomic subtypes using outcome-weighted integrative clustering
por: Arora, Arshi, et al.
Publicado: (2020)

PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA
por: Vitolo, U., et al.
Publicado: (2022)

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study
por: Belada, David, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qpm01t7mkmkj2q7l6jd37kjc55